|1.||Uto, Yoshihiro: 10 articles (08/2014 - 05/2002)|
|2.||Hori, Hitoshi: 9 articles (08/2014 - 05/2002)|
|3.||Ruggiero, Marco: 6 articles (02/2015 - 04/2011)|
|4.||Pacini, Stefania: 6 articles (02/2015 - 04/2011)|
|5.||Morucci, Gabriele: 6 articles (02/2015 - 04/2011)|
|6.||Gulisano, Massimo: 5 articles (02/2015 - 04/2011)|
|7.||Yamamoto, Nobuto: 5 articles (01/2009 - 09/2002)|
|8.||Inui, Toshio: 4 articles (08/2014 - 07/2013)|
|9.||Kuchiike, Daisuke: 4 articles (08/2014 - 07/2013)|
|10.||Kubo, Kentaro: 4 articles (08/2014 - 07/2013)|
01/01/2012 - "These results are consistent with the hypothesis that the known anticancer efficacy of DBP-MAF can be ascribed to different biological properties of the molecule that include inhibition of tumour-induced angiogenesis and direct inhibition of cancer cell proliferation, migration and metastatic potential."
01/01/2010 - "These studies show strong inhibitory activity of DBP-maf on prostate tumor cells independent of its macrophage activation."
01/01/2010 - "In this study we show for the first time that DBP-maf exhibits a direct and potent effect on prostate tumor cells in the absence of macrophages. "
08/01/2014 - "The current case study demonstrates that GcMAF and SDT can be used in combination with conventional therapies in patients with metastatic cancer, especially where treatment options are limited due to factors such as toxicity. "
07/01/2014 - "These observations demonstrate that OA, GcMAF and NO can be properly combined and specifically delivered to advanced cancer patients with significant effects on immune system stimulation and tumour volume reduction avoiding harmful side-effects."
|2.||Breast Neoplasms (Breast Cancer)
01/15/2008 - "Efficacy of GcMAF for treatment of metastatic breast cancer was investigated with 16 nonanemic patients who received weekly administration of GcMAF (100 ng). "
07/01/2013 - "In this study we demonstrate that GcMAF stimulates macrophages, which in turn attack human breast cancer cells, induce their apoptosis and eventually phagocytize them. "
04/01/2011 - "In addition, we demonstrate that GcMAF (1 ng/ml) inhibited prostaglandin E(1)- and human breast cancer cell-stimulated angiogenesis in chick embryo chorionallantoic membrane (CAM) assay. "
01/01/2012 - "DBP-MAF inhibited human breast cancer cell proliferation and cancer cell-stimulated angiogenesis. "
08/01/2014 - "Case report: A breast cancer patient treated with GcMAF, sonodynamic therapy and hormone therapy."
09/01/2003 - "Our studies indicate that, during inflammation DBP-maf may function positively by causing death of the macrophages when activated macrophages are no longer needed at the site of inflammation. "
11/01/2002 - "Gc protein has been reported to be a precursor of Gc protein-derived macrophage activation factor (GcMAF) in the inflammation-primed macrophage activation cascade. "
01/01/1999 - "The cure with subthreshold GcMAF-treatments (administered once or twice) of tumor-bearing mice appeared to be a consequence of sustained macrophage activation by inflammation resulting from the macrophage-mediated tumoricidal process. "
09/01/2004 - "Serum vitamin D-binding protein (Gc protein or DBP) is a highly expressed polymorphic protein, which is a precursor of the inflammation-primed macrophage activating factor, GcMAF, by a cascade of carbohydrate processing reactions. "
11/01/2005 - "The Gc protein (human group-specific component (Gc), a vitamin D-binding protein or Gc globulin), has important physiological functions that include involvement in vitamin D transport and storage, scavenging of extracellular G-actin, enhancement of the chemotactic activity of C5a for neutrophils in inflammation and macrophage activation (mediated by a GalNAc-modified Gc protein (GcMAF)). "
06/01/1998 - "Although malignant tumours are poorly immunogenic, 4 days after GcMAF-primed immunization of mice with heat-killed Ehrlich ascites tumour cells, the ascites tumour was no longer transplantable in these mice."
01/01/1999 - "Therefore, a protracted macrophage activation induced by a few administrations of minute amounts of GcMAF eradicated the murine ascites tumor."
07/01/2013 - "We also found that GcMAF-containing human serum significantly enhanced the phagocytic activity of mouse peritoneal macrophages and extended the survival time of mice bearing Ehrlich ascites tumors. "
|5.||Prostatic Neoplasms (Prostate Cancer)
01/01/2010 - "DBP-maf demonstrated inhibitory activity in proliferation studies of both LNCaP and PC3 prostate cancer cell lines as well as metastatic clones of these cells. "
01/01/2010 - "DBP-maf also had the ability to inhibit migration of prostate cancer cells in vitro. "
01/01/2010 - "Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells."
07/01/2008 - "Sixteen nonanemic prostate cancer patients received weekly administration of 100 ng of GcMAF. "
07/01/2008 - "Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF."
|1.||Cholecalciferol (Vitamin D3)
|2.||Thioctic Acid (Lipoic Acid)
|3.||Ascorbic Acid (Vitamin C)
|4.||vitamin D-binding protein-macrophage activating factor
|5.||Vitamin D-Binding Protein
|7.||Angiogenesis Inducing Agents (Angiogenesis Factor)
|10.||Urokinase Plasminogen Activator Receptors
|2.||Transplantation (Transplant Recipients)